These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26310546)

  • 21. Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment.
    Chua ME; See MC; Esmeňa EB; Balingit JC; Morales ML
    Low Urin Tract Symptoms; 2018 May; 10(2):135-142. PubMed ID: 28150436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Oral Sodium Bicarbonate and Solifenacin Treatment in Female Overactive Bladder Patients With Acidic Urine pH.
    Sönmez MG; Ecer G; Atici A; Özkent MS; İyisoy MS; Öztürk A
    Female Pelvic Med Reconstr Surg; 2020 Oct; 26(10):649-653. PubMed ID: 30335650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics.
    Cho KJ; Kim HS; Koh JS; Kim JC
    Int Urogynecol J; 2013 Feb; 24(2):325-30. PubMed ID: 22717785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients.
    Wang CC; Kuo HC
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):279-284. PubMed ID: 29843924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary nerve growth factor in women with overactive bladder syndrome.
    Liu HT; Chen CY; Kuo HC
    BJU Int; 2011 Mar; 107(5):799-803. PubMed ID: 20804479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in intraocular pressure and tear secretion in patients given 5 mg solifenacin for the treatment of overactive bladder.
    Turkoglu AR; Yener NP; Coban S; Guzelsoy M; Demirbas M; Demirci H
    Int Urogynecol J; 2017 May; 28(5):777-781. PubMed ID: 27844122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?
    Cardozo L; Herschorn S; Snijder R; Siddiqui E; Chapple CR
    Int Urogynecol J; 2017 Mar; 28(3):477-488. PubMed ID: 27605255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence.
    Kuo HC; Liu HT; Chancellor MB
    Neurourol Urodyn; 2010 Mar; 29(3):482-7. PubMed ID: 19367641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
    Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
    BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of urinary nerve growth factor for the diagnosis and assessment of the biofeedback success in children with dysfunctional voiding.
    Ergin G; Kibar Y; Ebiloğlu T; Irkılata HC; Kopru B; Kaya E; Uyanık M; Tapan S; Dayanc MM
    J Pediatr Urol; 2016 Apr; 12(2):118.e1-6. PubMed ID: 26701107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study.
    Henningsohn L; Kilany S; Svensson M; Jacobsen JL
    Aging Male; 2017 Dec; 20(4):266-276. PubMed ID: 28787230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder.
    Park HK; Kim HG; Yang DY; Choi WS; Paick SH; Chung H; Yang SK
    Low Urin Tract Symptoms; 2019 Jan; 11(1):56-60. PubMed ID: 28967201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome.
    Silva-Ramos M; Silva I; Oliveira O; Ferreira S; Reis MJ; Oliveira JC; Correia-de-Sá P
    PLoS One; 2013; 8(5):e64696. PubMed ID: 23741373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do Effects on Bowel Patterns Imposed by Solifenacin Always Have Negative Impacts on Treating Patients with Overactive Bladder (OAB)?
    Cho SY; Park S; Lee SB; Paick JS; Son H
    Low Urin Tract Symptoms; 2016 May; 8(2):106-12. PubMed ID: 27111622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary nerve growth factor could be a biomarker for interstitial cystitis/painful bladder syndrome: a meta-analysis.
    Qu HC; Zhang W; Yan S; Liu YL; Wang P
    PLoS One; 2014; 9(9):e106321. PubMed ID: 25181532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder.
    Liu HT; Kuo HC
    J Urol; 2008 Jun; 179(6):2270-4. PubMed ID: 18423678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reliability and validity of urinary nerve growth factor measurement in women with lower urinary tract symptoms.
    Vijaya G; Cartwright R; Bhide A; Derpapas A; Fernando R; Khullar V
    Neurourol Urodyn; 2016 Nov; 35(8):944-948. PubMed ID: 26227147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.